Tau PET imaging in cognitively normal elderly subjects: A twin approach

Recruiting

Conditions: Alzheimer's disease
dementia
10042258

Registration Number: NL-OMON55503

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 80

Inclusion Criteria

Inclusion in PreclinAD study (2014.210) and a subject must be older than 60
years, have received an [18F]flutemetamol amyloid PET scan and/or have a known
amyloid status obtained from CSF.

Exclusion Criteria

1.Has contra indications for MRI scanning and therefore has not received brain
MRI;
2.Has evidence of structural abnormalities such as major stroke or mass on MRI
that is likely to interfere with interpretation of PET scan;
3.Has a relevant history of severe drug allergy or hypersensitivity. Relevant
severe drug allergies should be determined by the Principal Investigator or
Co-Principal Investigator, and any questions about a subject*s eligibility can
be directed to Avid Radiopharmaceuticals Inc.;
4.Has ever participated in an experimental study with a tau agent, unless it
can be documented that the subject received only placebo during the course of
the trial;
5.Has been injected with a previously administered radiopharmaceutical within 6
terminal half-lives or when total yearly radiation exposure exceeds 16.1 mSv
for female and 22.4 mSv for male participants.
6.Has a history of severe traumatic brain

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main endpoints are the association of (longitudinal) tau pathology with amyloid<br /><br>pathology (CSF and/or PET) and the correlation in (longitudinal) tau pathology<br /><br>within monozygotic twin pairs. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are the relation between (longitudinal) tau and<br /><br>neuropsychological performance, magnetic resonance imaging(MRI), CSF measures<br /><br>and AD risk factors. </p><br>